Brief Report
Authors:
- Lynn PaxtonLPLynn Paxton
- Tony McLaurinTMTony McLaurin
- Allan TaylorATAllan Taylor
- Debra HansonDHDebra Hanson
- Walid HeneineWHWalid Heneine
- John T. BrooksJBJohn T. Brooks
- José Gerardo García-LermaJGJosé Gerardo García-Lerma
Open Access
- 1 June 2016
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 72 (2) , 129-132
Abstract
We describe HIV-1 evolutionary dynamics in the 4 participants from the TDF2-PrEP trial who became HIV-1 infected while prescribed emtricitabine and tenofovir disoproxil fumarate (FTC/TDF). At seroconversion, virus diversity in the 2 participants with detectable drug was only 0.05% (95% confidence intervals: 0.04 to 0.06) and 0.07% (0.06 to 0.08) compared with 2.25% (1.95 to 2.6) and 0.42% (0.36 to 0.49) in those with no detectable drug and 0.07%–0.69% in 5 placebo recipients (P > 0.5). At 10 months, diversity in adherent participants was only 0.37% (0.31 to 0.41) and 0.86% (0.82 to 0.90) compared with 0.5%–1.7% among participants who did not take FTC/TDF (P > 0.5). Although limited by the small number of infections that reduced the power to detect differences, we found that sequences from seroconverters with detectable drug were more homogeneous than those from placebo or nonadherent seroconverters.Keywords
This publication has 14 references indexed in Scilit:
- Antiretrovirals for Primary HIV Prevention: the Current Status of Pre- and Post-exposure ProphylaxisCurrent HIV/AIDS Reports, 2015
- Adherence to Preexposure Prophylaxis: Current, Emerging, and Anticipated Bases of EvidenceClinical Infectious Diseases, 2014
- CD4+ cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxisAIDS, 2014
- Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in BotswanaNew England Journal of Medicine, 2012
- HIV-1 envelope diversity 1 year after seroconversion predicts subsequent disease progressionAIDS, 2012
- Reduced Inflammation and CD4 Loss in Acute SHIV Infection During Oral Pre-Exposure ProphylaxisThe Journal of Infectious Diseases, 2012
- Delayed Maturation of Antibody Avidity but Not Seroconversion in Rhesus Macaques Infected With Simian HIV During Oral Pre-Exposure ProphylaxisJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Intermittent Prophylaxis with Oral Truvada Protects Macaques from Rectal SHIV InfectionScience Translational Medicine, 2010
- Deciphering Human Immunodeficiency Virus Type 1 Transmission and Early Envelope Diversification by Single-Genome Amplification and SequencingJournal of Virology, 2008
- Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell declineProceedings of the National Academy of Sciences, 1998